From NASH to MASH: Current Market Dynamics in Hepatology (Podcast) PodcastBack Bay Life Science AdvisorsOctober 8, 2024MASH, NASH, Hepatoglogy, Biotech development
Healthcare Capital Markets Update (Podcast) PodcastDNB//Back BayOctober 8, 2024Capital Markets, Healthcare, IPO, FPO, Partnering
Key Considerations for Healthcare Companies Listing on a US Exchange (Podcast) PodcastDNB//Back BayMay 23, 2024IPO, Healthcare, M&A
Orexo and Sofinnova Partners on Opportunities in Digital Therapeutics PodcastBack Bay Life Science AdvisorsApril 14, 2023Digital hralth, AI, Digital theraputics, EMEA, Tech, US Healthcare, Orexo, Soffinnova, Investment
Gene Editing to Cross-Species Transplantation: The Most Compelling Healthcare Stories of 2022 Podcast, Newsletter, Peter Bak, Brendan WangBack Bay Life Science AdvisorsJanuary 21, 2023Gene therapy, Gene Editing, Reumbursement, CRISPR
New Podcast with Back Bay and Nasdaq: Preparing Biopharma and Medtech Companies for Public Listing PodcastBack Bay Life Science AdvisorsSeptember 20, 2022Mergers, Podcast, Investment Banking, Public Listing, Biotech
Cell and Gene Therapy Investment Trends [Podcast] PodcastBack Bay Life Science AdvisorsNovember 22, 2021Cell Therapy, Gene Therapy, Investment, Industry Insights
A Conversation with SV Health Investors on Medtech Investment and Jonathan P. Gertler, BioVentures MedTech Funds [Podcast] PodcastBack Bay Life Science AdvisorsOctober 13, 2021Medtech investment, Medtech funds
Surging Investment in Remote Patient Monitoring [Podcast] PodcastBack Bay Life Science AdvisorsAugust 9, 2021Medtech, Wearables, Senors, Medtech investment
New Drug Pricing and Market Access [Podcast] PodcastBack Bay Life Science AdvisorsJuly 6, 2021Biotech, Market Access, Drug Pricing, FDA
Antimicrobials Investment [Podcast] PodcastBack Bay Life Science AdvisorsJune 16, 2021Anti-Infectives, Anti-Microbials, Investment
Back Bay Launches New Podcast for Life Science Insiders PodcastBack Bay Life Science AdvisorsJune 7, 2021Gene Therapy, SPACS, Anti-Infectives
